Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics

Across the recent three months, 7 analysts have shared their insights on 4D Molecular Therapeutics FDMT, expressing a variety of opinions spanning from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.0, a high estimate of $46.00, and a low estimate of $6.00. Observing a downward trend, the current average is 18.12% lower than the prior average price target of $37.86.

Decoding Analyst Ratings: A Detailed Look

The perception of 4D Molecular Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 4D Molecular Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for 4D Molecular Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of 4D Molecular Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on 4D Molecular Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering 4D Molecular Therapeutics: A Closer Look

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Unraveling the Financial Story of 4D Molecular Therapeutics

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Challenges: 4D Molecular Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -99.99%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: 4D Molecular Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1461433.33%, the company may face hurdles in effective cost management.

Return on Equity (ROE): 4D Molecular Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.68%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.16%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.